BD-1047 dihydrobromide is a selective sigma-1 (σ1) receptor antagonist with demonstrated antipsychotic-like activity in animal models, suggesting potential efficacy in the treatment of schizophrenia; it prevents Cutamesine-induced reduction of light exposure-induced cell death in murine photoreceptor-derived 661W cells; attenuates Cutamesine-mediated mitigation of mitochondrial damage and elevated caspase-3/7 activity; decreases apomorphine (APO)-induced climbing behavior in mice at a dose of 10 mg/kg (i.p.); counteracts the antidepressant-like effect induced by co-administration of pramipexole and sertraline (but not pramipexole and fluoxetine); reduces the increased expression of phosphorylated NR1 (pNR1) and reverses sigma-1 receptor agonist-potentiated NMDA-induced pain behavior and pNR1 immunoreactivity.